• Fusion protein inhibitor of VEGF
    • FDA approved for mCRC that is resistant to or has progressed following an oxaliplatin-containing regimen
    • Recommended dose: 4 mg/kg IV infusion over 1 hour every 2 weeks in combination with FOLFIRI
    • Half-life: 6 days
    • Common side effects: Hemorrhage, GI perforation, compromised wound healing (US box warning); nonhematologic: diarrhea, proteinuria, increased AST and ALT, stomatitis, fatigue, hypertension, weight reduced, decreased appetite, epistaxis, abdominal pain, dysphonia, increased serum creatinine, headache; hematologic: leukopenia, neutropenia, thrombocytopenia
    Other topics in Targeted and Immunotherapy Agents